Table 2.
Surgical and postoperative data
| No. of cases | Approach | CT‐guided marking | Blockade area | Blockade time (minutes) | FiO2 | Histopathological diagnosis | Postoperative complication | Additional treatment | Prognosis | Survival (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Thoracotomy | No | Left lower lobe | 111 | 0.6–0.9 | Ad | Acute exacerbation of IP | None | Dead | 19 |
| 2 | Thoracotomy | No | Right upper lobe | 60 | 1.0 | NTM | None | None | Alive | 84 |
| 3 | Thoracotomy | No | Left lower lobe | 50 | 1.0 | ACC | None | None | Alive | 75 |
| 4 | VATS | Yes | Right basal segment | 30 | 1.0 | SqCC | None | Carbon‐ion radiotherapy | Alive | 75 |
| 5 | VATS | Yes | Right lower lobe | 57 | 1.0 | Ad | None | ALK inhibitor | Alive | 34 |
| 6 | VATS | No | Left basal segment | 58 | 1.0 | Ad | None | Chemotherapy, ICI | Dead | 18 |
ACC, adenoid cystic carcinoma; Ad, adenocarcinoma; ALK, anaplastic lymphoma kinase; CT, computed tomography; FiO2, fraction of inspired oxygen; ICI, immune checkpoint inhibitor; IP, interstitial pneumonia; NTM, nontuberculous mycobacteriosis; SqCC, squamous cell carcinoma; VATS, video‐assisted thoracoscopic surgery.